Compare DOGZ & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOGZ | PHIO |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 12.9M |
| IPO Year | 2017 | 2011 |
| Metric | DOGZ | PHIO |
|---|---|---|
| Price | $0.73 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.6K | ★ 93.7K |
| Earning Date | 09-30-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.81 |
| 52 Week High | $15.61 | $4.19 |
| Indicator | DOGZ | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 22.81 | 28.55 |
| Support Level | N/A | $0.83 |
| Resistance Level | $0.96 | $1.12 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.00 | 6.76 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.